AbbVie Inc (ABBV): AbbVie's CEO Discusses Q3 2013 Results - Earnings Call ... Seeking Alpha In addition to assets currently in late-stage such as HCV, daclizumab, elagolix, (inaudible) and elotuzumab were on the cusp of transitioning several additional programs in the Phase 3 development, including but not limited to ABT-199 per CLL and ABT ... |
